ライフサイエンスコーパス: intranasal

1 ed-masked ITN treatments (sham extranasal or intranasal).

2 Intranasal 9cRA can facilitate the functional recovery a

3 The pharmacokinetic properties of intranasal absorption were dependent on the concentratio

4 this question by contrasting two methods of intranasal administration (a standard nasal spray, and a

5 eficient mice were infected with H1N1 PR8 by intranasal administration and course of influenza pneumo

6 Live-attenuated pediatric vaccines for intranasal administration are being developed for human

7 h the CNS and the cellular CNS targets after intranasal administration are not fully understood.

8 These results suggest that intranasal administration bypasses the blood-brain barri

9 or, accumulates in cerebrospinal fluid after intranasal administration in macaques and humans and mod

10 fective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and establish

11 Intranasal administration of a single dose of MMI-Ps1 im

12 Therefore, this study compared intranasal administration of AgNPs versus soluble silver

13 Intranasal administration of allergen induced rises of a

14 Intranasal administration of Alternaria challenge reduce

15 n the responses in humans receiving a single intranasal administration of BPZE1.METHODSWe performed m

16 Intranasal administration of ChAd-SARS-CoV-2-S is a cand

17 Stimulation of transplanted cells with daily intranasal administration of CTZ enhanced axonal myelina

18 Intranasal administration of either IL-4 or IL-13 confer

19 h the expression and identity task after the intranasal administration of either OT or saline in a wi

20 More important, replenishment of Sema3E by intranasal administration of exogenous Sema3E protects m

21 10Ralpha) knockout mice by means of repeated intranasal administration of house dust mite (HDM).

22 rway disease was induced in mice by repeated intranasal administration of house dust mite or the fung

23 Mice received unilateral intranasal administration of lipopolysaccharide (LPS) or

24 To investigate the effect of intranasal administration of major birch pollen allergen

25 ses of allergen-specific IgE levels, whereas intranasal administration of omalizumab did not enhance

26 xamined pairs of friends while dancing after intranasal administration of OT or placebo.

27 cognition and behavior, we examined whether intranasal administration of OT would modulate synchroni

28 We have shown that prophylactic intranasal administration of our lead fusion inhibitor e

29 inconsistencies observed following systemic intranasal administration of OXT and provide important i

30 In tPA knockout mice, intranasal administration of recombinant tPA protein 6 h

31 Importantly, intranasal administration of rIFN-gamma largely rescued

32 Intranasal administration of the adenosine receptor anta

33 acquired at 22-28 and at 30-36 minutes post-intranasal administration.

34 detected in the CNS within minutes following intranasal administration.

35 reaches the brain following intravenous and intranasal administration.

36 e arm at 0, 1, and 4 months, followed by two intranasal administrations of 30 mug unadjuvanted vaccin

37 placebo-controlled 6-week trials of repeated intranasal administrations of oxytocin (48 IU/day) in ad

38 Based on the fact that intranasal allergen application induces rises of systemi

39 later, inflammation was induced by rectal or intranasal allergen challenge and monitored by mini endo

40 IL-6 was observed in nasal mucosa following intranasal allergen challenge in the GPA group but not i

41 ed in global IL-4Ralpha-deficient mice after intranasal allergen challenge.

42 show promise, each must be tested with both intranasal and intracranial administration to ensure the

43 ) was less pathogenic than wild-type VACV in intranasal and intradermal models of infection.

44 attenuated for virulence in mice by both the intranasal and intradermal routes of infection.

45 are used to co-infect donor ferrets via the intranasal and intratracheal routes to cause an upper an

46 , and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes(9,10).

47 eases in systemic circulation following both intranasal and intravenous OT administration.

48 ly susceptible to orthopoxvirus infection by intranasal and systemic routes.

49 antibodies prior to challenge infection, and intranasal antibodies increased rapidly postchallenge.

50 ation of an intranasal corticosteroid and an intranasal antihistamine for initial treatment.

51 therapy with intranasal corticosteroid plus intranasal antihistamine is more effective than either a

52 nefit of combination treatment with INCS and intranasal antihistamines in both AR and NAR.

53 Either intranasal antihistamines or INCS may be offered as firs

54 Upon intranasal application in mice, VNP expressing surface-e

55 C57BL/6 mice received a single intranasal application of equimolar amounts of IL-5, IL-

56 oth models, we demonstrated that therapeutic intranasal application of hBD2 significantly reduced the

57 nd increased airway responsiveness following intranasal aspergillus sensitization.

58 m, n = 8; diazepam, n = 3), and 27 recommend intranasal benzodiazepines (midazolam, n = 27; lorazepam

59 Acute intranasal, but not intraperitoneal, leptin decreased th

60 cci were preincubated with human sIgA before intranasal challenge in a mouse model of colonization.

61 s confer resilience to ASF we established an intranasal challenge model with a moderately virulent AS

62 Intranasal challenge of mice epicutaneously sensitized w

63 (HMW-TT) conferred better protection against intranasal challenge than a conjugate made with the LMW

64 5) CFU (80,000 50% lethal dose [LD(50)]) and intranasal challenge with 5 x 10(3) CFU (50 LD(50)) of v

65 U of influenza A virus MEM H3N2, followed by intranasal challenge with 5 x 10(7) CFU of NTHi R2866 Sp

66 Intranasal challenge with Bet v 1 induced increases in B

67 R1(-/-) mice survived subsequent lethal VACV intranasal challenge, or defects of T cell activation or

68 h pollen were added to the allergen prior to intranasal challenge.

69 d bronchial inflammation were analyzed after intranasal challenges with allergen or PBS.

70 In vivo, intranasal chitosan affected occludin expression and fac

71 Intranasal co-delivery of miR-18a and NEO100, a good man

72 linician may recommend the combination of an intranasal corticosteroid and an intranasal antihistamin

73 an intranasal corticosteroid rather than an intranasal corticosteroid in combination with an oral an

74 persons aged 15 years or older, recommend an intranasal corticosteroid over a leukotriene receptor an

75 Combination therapy with intranasal corticosteroid plus intranasal antihistamine

76 der, routinely prescribe monotherapy with an intranasal corticosteroid rather than an intranasal cort

77 r with bilateral CRSwNP and symptoms despite intranasal corticosteroid use, receiving systemic cortic

78 no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (wo

79 Although the main symptomatic treatments are intranasal corticosteroids (INCS) (daily or on demand) a

80 Intranasal corticosteroids (INCS) remain the preferred m

81 uroate in patients with CRSwNP refractory to intranasal corticosteroids (INCS) significantly improved

82 ost common intranasal medications containing intranasal corticosteroids and 8 oral H(1)-antihistamine

83 l, intranasal or ocular H(1)-antihistamines, intranasal corticosteroids or a fixed combination of int

84 ults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omal

85 in severe CRSwNP with inadequate response to intranasal corticosteroids, and it was well tolerated.

86 Intranasal costimulation with the lipopeptide Toll-like

87 lude an INCS may be offered, in addition, an intranasal decongestant for up to 4 weeks.

88 While intranasal decongestants generally should be limited to

89 ver residence time in the sinus cavity after intranasal delivery of AgNPs and AgNO3 to mice, and char

90 Intranasal delivery of CXCL10 siRNA blocked Th1 infiltra

91 Intranasal delivery of IL-4 nanoparticles after ICH hast

92 Consistent with these findings, intranasal delivery of IL-4 nanoparticles after stroke i

93 ons with PTD represent a useful platform for intranasal delivery of insulin and other biomolecules.

94 Intranasal delivery of neuroprotective ST266 is a potent

95 loped from Quil-A and chitosan (QAC) for the intranasal delivery of nucleic acid immunogens to improv

96 Intranasal delivery of ornithine or imidazole or the two

97 This phenotype was reversed by intranasal delivery of recombinant r-IL-33.

98 Intranasal delivery of the siRNA targeting Beclin1 signi

99 egative children aged 6-24 months received 1 intranasal dose (105 plaque-forming units [PFUs] of D46/

100 egative children ages 6-24 months received 1 intranasal dose of 105 plaque-forming units (PFU) of LID

101 In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels

102 Healthy children received a single, intranasal dose of LAIV containing the 2011-2012 recomme

103 A single intranasal dose of RSV/DeltaNS2/Delta1313/I1314L was eva

104 Calves receiving a single, intranasal dose of the BRSV-NP vaccine are partially pro

105 quence (blocks of six) to receive either two intranasal doses (0.25 mL per nostril) of LAIV H5N2 (101

106 Sensitizing intranasal doses of an extract from the house dust mite

107 These results indicate that the intranasal drug delivery allows for the direct delivery

108 ed with wild-type (WT) littermates following intranasal exposure to HDM allergen.

109 upational allergic rhinitis mainly caused by intranasal exposure to wheat and/or rye flour in bakery

110 Intranasal exposure with receptor agonists induced the r

111 oxin adjuvant that improves protection of an intranasal flu vaccination by a mechanism that does not

112 ctivated vaccine (n = 16) or placebo (n = 5, intranasal followed by intramuscular; n = 10, twice intr

113 has taken on added importance because a new intranasal formulation of desmopressin was approved by t

114 An intranasal formulation of esketamine, the S enantiomer o

115 Focused ultrasound-mediated intranasal (FUSIN) delivery is a recently proposed techn

116 The clinical efficacy of oral and intranasal gepants and the injectable CGRP monoclonal an

117 al corticosteroids or a fixed combination of intranasal H(1)-antihistamines and corticosteroids.

118 Asthma was induced in mice using intranasal house dust mite or aerosol ova-albumin challe

119 -) mice, Rel(C307X) mice were susceptible to intranasal HSV-1 infection.

120 ccines expressing clade B HIV-1 gp160 by the intranasal (i.n.) and i.m. routes to compare mucosal and

121 g(10) CFU following subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost, resp

122 anchored form of EBOV glycoprotein GP, as an intranasal (i.n.) EBOV vaccine.

123 llergic reactivity following repeated weekly intranasal (i.n.) GSK2245035.

124 3-fold higher antigen dose was required for intranasal (i.n.) immunization with gp120 to induce seru

125 show that intestinal mucosa is infected via intranasal (i.n.) or per-oral (p.o.) Chlamydia inoculati

126 vaccine regimen in pigtail macaques using an intranasal (i.n.) recombinant Fowl Pox Virus (FPV)-gag p

127 However, a four-week intranasal IFNbeta treatment of HIVgp120tg mice starting

128 antibodies combined with rapidly increasing intranasal IgG4/7 antibodies and lack of nasal type I in

129 Administration of intranasal IL-33 and TSLP was sufficient for mucous meta

130 Therefore, intranasal IL-4 delivery may represent a novel therapeut

131 Intranasal IL-4 treatment warrants further investigation

132 protection against G. lamblia infection upon intranasal immunization in rodent models of giardiasis.

133 We showed previously that intranasal immunization with dsc(19)CfaE, a soluble vari

134 In both species, a single dose of intranasal immunization with PIV5-vectored vaccines was

135 Two days after intranasal immunization with PS-GAMP-adjuvanted H1N1 vac

136 Focused ultrasound-enhanced intranasal (IN + FUS) delivery is a noninvasive approach

137 Here, we examined the effects of intranasal (IN) administration of extracellular vesicles

138 Intranasal (IN) administration, an alternative route for

139 tion that resembled M2-null virus, following intranasal (IN) infection of mice that express Cre in al

140 bility at high temporal resolution following intranasal (IN) naloxone administration to healthy volun

141 We have demonstrated an intranasal (IN) nanoemulsion adjuvant that redirects all

142 As OT is a peptide, delivery by the intranasal (IN) route is the preferred method in clinica

143 Intranasal infection with attenuated RABV prolonged the

144 were more susceptible than wild-type mice to intranasal infection with Burkholderia thailandensis Pro

145 njection at varying doses, 24 hours prior to intranasal infection with H5N1 and H7N9 viruses for prop

146 and African green monkeys received a primary intranasal infection with RSV and were given a boost wit

147 able on their presence in the early stage of intranasal infection.

148 Intranasal inflammatory markers were not detectable in p

149 ion against H3N8 CIV challenge with a single intranasal inoculation in mice.

150 Intranasal inoculation in postnatal day 14 mice with VSV

151 Spec(r) Mice were pretreated or not with an intranasal inoculation of 5 x 10(7) CFU M. muris 24 h be

152 cit the previously characterized response to intranasal inoculation of GAS.

153 disease phenotype than wild-type mice after intranasal inoculation of RABV.

154 Intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice r

155 Following a single intranasal inoculation, both animal species shed the vac

156 bated for 2 weeks, followed by P. aeruginosa intranasal inoculation.

157 with influenza A/Wisconsin/67/2005 (H3N2) by intranasal inoculation; 35 healthy control subjects were

158 infections but this defect is overcome by intranasal installation of a TLR2/6 agonist and a MAIT c

159 s connected to the olfactory bulbs following intranasal instillation of H1N1 in Rag knockout mice.

160 in individuals with allergic asthma and the intranasal instillation of HDM in mice resulted in incre

161 Intranasal instillation of IFN-gamma-neutralizing antibo

162 Intranasal instillation of IL-22 with TNF-alpha, but not

163 o HDM challenge than WT counterparts because intranasal instillation of the allergen induced markedly

164 Intranasal instillation was used to achieve pulmonary de

165 exposed to 330 mug of Mn (MnCl(2) 30 mg/kg, intranasal instillation, daily) for 3 weeks.

166 rmacokinetics for inhalational treatment and intranasal insufflation delivery of CDPL-GW nanoprobe am

167 in random order, study participants received intranasal insulin (60 IU) or placebo (8.7% sodium chlor

168 The next day, they were administered either intranasal insulin (60 IU) or placebo, following which t

169 Intranasal insulin administration has been hypothesised

170 Moreover, in healthy mice, intranasal insulin administration increased mitochondria

171 Intranasal insulin also increased circulating cortisol l

172 Insulin deficiency and intranasal insulin alter brain mitochondrial function: a

173 Insulin spillover into circulation after intranasal insulin application was mimicked by an intrav

174 Our data indicates that intranasal insulin can reach cellular CNS targets along

175 Clinical trials have also shown that intranasal insulin elicits beneficial cognitive effects

176 key factors for successful development of an intranasal insulin formulation is an absorption enhancer

177 Pre-clinical studies have shown that intranasal insulin is neuroprotective in models of Alzhe

178 In our study, intranasal insulin normalized the subjective and hormona

179 On two separate days, participants received intranasal insulin or placebo.

180 Similarly, in the second study, intranasal insulin reduced nicotine cravings over time (

181 As such, intranasal insulin should further be studied in a larger

182 in reinstatement of drug use, we formulated intranasal insulin to evaluate its efficacy during acute

183 a remarkable increase in bioavailability of intranasal insulin, causing a significant decrease in bl

184 t into the potential therapeutic benefits of intranasal insulin.

185 A single intranasal/intratracheal inoculation of juvenile baboons

186 Intranasal introduction of A. baumannii OMVs mediated pu

187 The protective effect of intranasal IRL201104 against OVA-induced eosinophilia pe

188 In mice with DIO, intranasal leptin bypassed leptin resistance and signifi

189 Chronic intranasal leptin decreased food intake and body weight,

190 Intranasal leptin induced signal transducer and activato

191 We propose that intranasal leptin will bypass leptin resistance and trea

192 hort of children following immunization with intranasal live attenuated influenza vaccine, suggesting

193 lent inactivated influenza vaccine [TIV] vs. intranasal live, attenuated influenza vaccine [LAIV]) wa

194 e vaccine regimens included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed by

195 ypothesis, we established a mouse model with intranasal LPS instillation in the presence or absence o

196 In vaccination studies, intranasal LTA1 enhanced immune responses to inactivated

197 We conclude that intranasal MAIT cell priming in mice induces early MAIT

198 The 4 most common intranasal medications containing intranasal corticoster

199 andomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks.

200 Parents were assigned to intranasal mupirocin and 2% chlorhexidine-impregnated cl

201 ents colonized with S aureus, treatment with intranasal mupirocin and chlorhexidine-impregnated cloth

202 imen included hygiene education, twice-daily intranasal mupirocin, and daily bleach-water baths.

203 , and 1 trial found that lower-concentration intranasal naloxone (2 mg/5 mL) was less effective than

204 imilar efficacy between higher-concentration intranasal naloxone (2 mg/mL) and intramuscular naloxone

205 Higher-concentration intranasal naloxone (2 mg/mL) seems to have efficacy sim

206 Labeled oxytocin is quantified after intranasal (not intravenous) administration in brain reg

207 After intranasal NTHi challenge, colonization of the murine na

208 hs (active treatment, n = 117) or petrolatum intranasal ointment and nonmedicated soap cloths (placeb

209 Intranasal or intraperitoneal administration of a single

210 sed pharmacological treatments include oral, intranasal or ocular H(1)-antihistamines, intranasal cor

211 ity of DeltaantC-infected mice challenged by intranasal or subcutaneous routes was 20% greater than w

212 nding bNAbs administered through the airway (intranasal or via nebulization) versus the systemic rout

213 This dissociation provides evidence that intranasal OT affects primate behavior under very partic

214 e aim of this study was to determine whether intranasal OT has a general anxiolytic effect on the per

215 mals, there is considerable debate as to how intranasal OT influences primate behavior.

216 After epithelial barrier disruption, intranasal OVA application induced higher OVA-specific I

217 C57BL/6 mice were exposed to a first set of intranasal OVA challenge under SD or healthy sleep (HS)

218 airway infiltration and decreased AHR after intranasal OVA challenge.

219 hil-dominated airway inflammation and AHR on intranasal OVA challenge.

220 tive sensitization was attempted by repeated intranasal ovalbumin (OVA) applications in Naive mice.

221 imed at targeting amygdala functioning using intranasal OXT administration.

222 muli and a non-social control odor following intranasal OXT or PLC administration, respectively.

223 ng and may be part of the mechanism by which intranasal OXT shows promise for therapeutic benefit in

224 Many reports have described the efficacy of intranasal OXT therapy to improve the core symptoms of p

225 tested the efficacy and tolerability of 4-wk intranasal OXT treatment (24 International Units, twice

226 We assessed the effect of intranasal oxytocin (24 IU) administered to 29 healthy,

227 -controlled crossover study with single-dose intranasal oxytocin (24 IU) in ten overweight or obese,

228 wenty-four normal weight volunteers received intranasal oxytocin (24 IU) or placebo in a double-blind

229 ticipants were randomly assigned to a 6-week intranasal oxytocin (48IU/day, n = 53) or placebo (n = 5

230 20; 85% accident victims) were randomized to intranasal oxytocin (8 days/40 IU twice daily) or placeb

231 The efficacy and reliability of using intranasal oxytocin (OT) to clinically enhance social fu

232 Clinical trials using intranasal oxytocin (OXT) show promise to improve feedin

233 Intranasal oxytocin administration amplified this amygda

234 Both intranasal oxytocin administration and chemogenetic stim

235 f non-alcoholic palatable solutions, whereas intranasal oxytocin administration did not.

236 Intranasal oxytocin administration early after trauma ma

237 Therefore, we investigated the effects of intranasal oxytocin administration early after trauma on

238 Intranasal oxytocin administration suppressed hypothalam

239 o, but no significant difference between 8IU intranasal oxytocin and either 24IU intranasal oxytocin

240 re was no significant difference between 8IU intranasal oxytocin and IV oxytocin on right amygdala ac

241 in Labelling on 2 occasions, once after 40IU intranasal oxytocin and once after placebo.

242 eter, the significant difference between 8IU intranasal oxytocin and placebo is consistent with the h

243 ts revealed reduced pupil diameter after 8IU intranasal oxytocin compared to placebo, but no signific

244 Intranasal oxytocin delivery fully replicated these effe

245 ral clinical trials examining the effects of intranasal oxytocin for improving social and behavioral

246 To date, the brain tissue penetrance of intranasal oxytocin has not been demonstrated.

247 ealthy males indicates that a single dose of intranasal oxytocin has positive effects on social funct

248 eceptor (5-HT1AR) function is modified after intranasal oxytocin intake.

249 ncreases in salivary oxytocin observed after intranasal oxytocin most likely reflect unabsorbed pepti

250 tor antagonist did not reverse the effect of intranasal oxytocin on alcohol drinking.

251 The present study examined the effects of intranasal oxytocin on hippocampal blood flow in CHR-P i

252 ween 8IU intranasal oxytocin and either 24IU intranasal oxytocin or IV oxytocin treatment conditions.

253 ent findings, we cannot recommend continuous intranasal oxytocin treatment alone at the current dose

254 conditions-including two different doses of intranasal oxytocin using a novel Breath Powered nasal d

255 No effects of intranasal oxytocin were seen in reward circuits or on a

256 eter and right amygdala activation after 8IU intranasal oxytocin.

257 3,4-methylenedioxymethamphetamine (MDMA) and intranasal oxytocin.

258 ata confirmed the utility of a pig model for intranasal particulate flu vaccine delivery platform to

259 83% of animals treated with a combination of intranasal PC945 and oral posaconazole survived until da

260 nicity and should be further developed as an intranasal pediatric vaccine.IMPORTANCE RSV and HPIV1 ar

261 Mouse mortality was monitored after intranasal pneumococcal challenge.

262 with a PAR-2 agonist peptide (PAR-2AP) in an intranasal prime boost approach increased survival of mi

263 -2 infection of cells in vitro, and a single intranasal prophylactic dose of decoy protected Syrian h

264 We evaluated an intranasal recombinant Fowlpox virus (rFPV) priming vacc

265 (11/11) and all except one immunized by the intranasal route (5/6) survived.

266 andidates were tested in BALB/c mice via the intranasal route and induced both humoral and cell-media

267 The intranasal route appeared as an attractive and alternati

268 9cRA or vehicle was given via an intranasal route daily starting from day 3.

269 These findings suggest that the intranasal route of administration is able to effectivel

270 bust evidence confirming the validity of the intranasal route to target specific brain regions.

271 eys with the Bangladesh strain of NiV by the intranasal route using the laryngeal mask airway (LMA) m

272 Mice were immunized through the intranasal route with house dust mite (HDM) extract deri

273 nsport LENK exclusively to the brain via the intranasal route, with no peripheral exposure and nanopa

274 iary clearance curtail the efficiency of the intranasal route.

275 Typhi, and survived lethal intranasal S. sonnei challenge.

276 solated enzymatic A1 domain of LT (LTA1) for intranasal safety and efficacy in combination with influ

277 Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in s

278 However, after in vivo intranasal sensitization and challenge with HDM, DC-spec

279 Intranasal spray application facilitates insulin deliver

280 12 (33%) of 36 after prime immunisation with intranasal study product or placebo, and in 18 (32%) of

281 o, in 22 (61%) of 36 after immunisation with intranasal study product or placebo, and in 21 (38%) of

282 peroxide (H(2)O(2)) we developed a model of intranasal supplementation of polyethylene glycol-conjug

283 s to investigate the effects of the Allergan Intranasal Tear Neurostimulator (ITN) on conjunctival go

284 concept, 6-week, open-label clinical trial, intranasal theophylline (an epithelial membrane transpor

285 esults regarding olfactory improvement using intranasal theophylline warrant confirmation in a random

286 Importantly, intranasal transfer of bone marrow-derived M-MDSCs from

287 Intranasal treatment of mice with DK128 conferred protec

288 Daily intranasal treatment of wild-type mice with C3a beginnin

289 mulates post-ischaemic neural plasticity and intranasal treatment with C3a receptor agonists is an at

290 Intranasal treatment with either of the variants increas

291 tigated the beneficial effects of preventive intranasal treatment with probiotics Lactobacillus rhamn

292 Intranasal treatment with recombinant Sema3E significant

293 Intranasal treatment with the synthetic glucocorticoid f

294 Intranasal vaccination was not associated with a higher

295 may develop nasal congestion as a result of intranasal vaccination.IMPORTANCE Despite decades of res

296 mutation in the P/C gene (C(Delta170)) as an intranasal vaccine vector to express the EBOV glycoprote

297 Rationale: Needle-free intranasal vaccines offer major potential advantages, es

298 se results have significant implications for intranasal vaccines, which deliver antigen to mucosal-as

299 mutant AB(5) adjuvant proteins were added to intranasal vaccines.

300 th vDeltaA55 induced increased protection to intranasal VACV challenge compared to the level with con